论文部分内容阅读
目的探讨盐酸多奈哌齐联合灯盏生脉胶囊治疗脑卒中后认知功能障碍的临床疗效及安全性。方法选择我院2015年1月至12月收治的脑卒中后认知功能障碍患者120例,随机分为对照组和观察组,各60例。对照组给予盐酸多奈哌齐一日5 mg,观察组患者在对照组基础上加用灯盏生脉胶囊(2粒/次、一日3次),疗程均为12周。采用蒙特利尔认知功能评定量表(MoCA)评定患者的认知功能、临床痴呆评定量表(CDR)评定患者的痴呆严重程度、日常生活活动能力量表(ADL)评价患者生活自理能力。结果两组患者治疗后MoCA评分和Barthel指数评分均升高、CDR评分均降低,且与治疗前比较,差异均具有统计学意义(P<0.05);观察组患者治疗后MoCA评分和Barthel指数评分升高程度、CDR评分降低程度均比对照组更为显著,且差异均具有统计学意义(P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。结论盐酸多奈哌齐联合灯盏生脉胶囊对脑卒中后认知功能障碍的临床疗效确切,并可改善患者的认知功能,提高患者生活质量,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of donepezil hydrochloride combined with Dengzhan Shengmai Capsule in the treatment of cognitive dysfunction after stroke. Methods A total of 120 patients with cognitive dysfunction after stroke admitted from January 2015 to December 2015 in our hospital were randomly divided into control group and observation group, with 60 cases in each group. The control group was given donepezil hydrochloride on the 1st 5 mg. Patients in the observation group were treated with Dengzhan Shengmai capsule (2 capsules / time three times a day) on the basis of the control group for 12 weeks. The Montreal Cognitive Function Rating Scale (MoCA) was used to evaluate the cognitive function of patients. The clinical dementia rating scale (CDR) was used to assess the severity of dementia and ADL to evaluate the self-care ability of patients. Results After treatment, MoCA score and Barthel index score increased, CDR score decreased, and the difference was statistically significant (P <0.05). After treatment, MoCA score and Barthel index score (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05) .2. Conclusions Donepezil hydrochloride combined with Dengzhan Shengmai Capsule has definite curative effect on cognitive dysfunction after stroke and can improve cognitive function and improve quality of life of patients, which deserves clinical application.